Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
Saved in:
| Title: | Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder. |
|---|---|
| Authors: | Di Salvo J; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey jerry.disalvo@evotec.com., Nagabukuro H; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Wickham LA; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Abbadie C; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., DeMartino JA; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Fitzmaurice A; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Gichuru L; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Kulick A; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Donnelly MJ; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Jochnowitz N; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Hurley AL; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Pereira A; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Sanfiz A; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Veronin G; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Villa K; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Woods J; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Zamlynny B; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Zycband E; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Salituro GM; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Frenkl T; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Weber AE; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Edmondson SD; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey., Struthers M; Discovery and Preclinical Sciences, Merck Research Laboratories, Kenilworth, New Jersey. |
| Source: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2017 Feb; Vol. 360 (2), pp. 346-355. Date of Electronic Publication: 2016 Dec 13. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
